CELC
Celcuity Inc.
Healthcare · Biotechnology · NCM
$88.28
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
MODERATE
Data Confidence: 57.1%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$6.6B
Total market value of the company
Trailing P/E
N/A
Forward P/E
-100.16
Based on estimated future earnings — lower means cheaper
Rev Growth
N/A
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
ROE
-163.8%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$159.90
+81% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 10 analysts covering this stock
About Celcuity Inc.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

https://www.celcuity.com

Country: United States Employees: 155 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
4.9% PASS
Debt must be below 33% of total assets
Cash Ratio
6.8% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
1.224
Excellent risk-adjusted returns
Kelly Fraction
0.1722
Suggested allocation is meaningful — the edge justifies a position
Calmar Ratio
3.504
Returns exceed worst-case losses — strong risk profile
Annual Return
200.2%
Historical annualised return based on price data
Max Drawdown
-57.1%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
16
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.09
Very low correlation to market moves
52W High
$151.02
42% below the year high
52W Low
$10.26
760% above the year low
Avg Volume
867,503
Average daily shares traded — higher means easier to buy and sell
Short Ratio
12.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
27.9%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-3.79
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
3.20
Heavy leverage — higher financial risk if revenues decline
Current Ratio
10.55
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
10.00
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-96,047,504
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-177,042,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
10
Target High
$189.00
Target Median
$159.90
Target Low
$138.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-19 BULLER RICHARD E Director 1,029 —
2026-05-04 DALVEY DAVID F Director 25,000 $3,517,000
2026-05-04 BULLER RICHARD E Director 9,000 $1,264,181
2026-05-04 BULLER RICHARD E Director 9,000 $45,900
2026-04-09 NIGON RICHARD J Director 10,000 —
2026-03-31 BULLER RICHARD E Director 3,000 $330,804
2026-03-31 BULLER RICHARD E Director 3,000 $15,300
2026-02-11 ROMP CHARLES R Director 215 —
2026-01-27 DALVEY DAVID F Director 20,000 $2,400,538
2025-12-15 NIGON RICHARD J Director 19,975 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.